After Aerovate's stock crashed 93% a few months ago, the company is coming under the wing of new biotech Jade. ByGabrielle MassonOct 31, 2024 03:03pm SubscribeToday Biotech AbbVie pays $65M for options on EvolveImmune's T-cell engagers ...
Fierce Biotech Associate Editor Gabrielle Masson presented the 2024 Fierce 15 winners on the floor of the New York Stock Exchange on Wednesday. Annalee ArmstrongAug 8, 2024 12:00am Sponsored Dell Technologies on the data transformation in life sciences ...
The failure of the FGF21 analog to significantly reduce fibrosis in cirrhotic NASH patients sent Akero’s stock tumbling. ByNick Paul TaylorOct 10, 2023 08:00am Biotech Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
South San Francisco-based Septerna isoffering16 million shares of stock at an initial price of $18, with an additional 2.4 million shares available over the next 30 days at the public offering price. The company expects to generate $288 million from the IPO and close the deal on Monday. T...
This has been the year of the preclinical biotech cash out: So many early-stage, promising young startups have gone public earlier than ever before. Or they've sold to an opportunistic pharma, sometimes with a big-bucks bet that a platform or asset would be a big mover for its pipeline...
Layoffs rose 57% this year compared to 2022, with 187 workforce reductions in 2023 compared to 119, according to an analysis of Fierce Biotech data.
separation. The biotech touts its process as using a “simple” benchtop format that would be accessible in other facilities where therapies are developed. Supplies for the construction of the radiotherapies is “streamlined” and decentralized, with materials originating from nuclear industry stockpiles...
government has provided around $100 million in funding to help bring the program forward, in the hope that it may be useful for pandemic stockpiling. A couple of years ago, Ansun reported that DAS181 also seems to block the attachment of two other respiratory pathogens—respiratory syncytial ...
Shortly thereafter, he founded his first company, PerSeptive Biosystems, which was acquired in 1998 in a $360 million all-stock deal by Perkin-Elmer (which later became Applera). Afeyan became the SVP and CBO of Applera where he oversaw the creation of Celera Genomics. ...
When trading began on Friday, Embecta—using the ticker symbol “EMBC”—opened at a stock price of $32.50 but quickly dropped below the $30 mark in the first few minutes of trading. Related BD finalizes name and leadership for its billion-dollar diabetes spinoff ...